Evoke Pharma Inc (EVOK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evoke Pharma Inc (EVOK) has a cash flow conversion efficiency ratio of -0.155x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-521.96K) by net assets ($3.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see EVOK market cap for the company's overall valuation and market capitalisation.
Evoke Pharma Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Evoke Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Evoke Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evoke Pharma Inc ranked by their cash flow conversion efficiency. See EVOK debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shinhwa Contech Co. Ltd
KQ:187270
|
0.005x |
|
SUNation Energy Inc.
NASDAQ:SUNE
|
-0.054x |
|
Energoaparatura S.A.
WAR:ENP
|
-0.358x |
|
Hubei Geoway Investment Co Ltd
SHG:600462
|
0.893x |
|
RENN Fund Inc
NYSE MKT:RCG
|
-0.001x |
|
Marwynn Holdings, Inc. Common stock
NASDAQ:MWYN
|
-0.172x |
|
SeaTwirl AB
ST:STW
|
-0.076x |
|
NBT Inc.
KQ:236810
|
-0.011x |
Annual Cash Flow Conversion Efficiency for Evoke Pharma Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Evoke Pharma Inc from 2011 to 2024. View Evoke Pharma Inc (EVOK) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.04 Million | $-5.46 Million | -0.776x | -140.13% |
| 2023-12-31 | $-2.58 Million | $-4.98 Million | 1.933x | +219.67% |
| 2022-12-31 | $4.08 Million | $-6.60 Million | -1.615x | +53.53% |
| 2021-12-31 | $3.56 Million | $-12.35 Million | -3.475x | -268.47% |
| 2020-12-31 | $-3.21 Million | $-6.63 Million | 2.062x | +256.79% |
| 2019-12-31 | $4.38 Million | $-5.76 Million | -1.315x | +24.13% |
| 2018-12-31 | $4.03 Million | $-6.98 Million | -1.734x | +56.93% |
| 2017-12-31 | $2.17 Million | $-8.72 Million | -4.025x | -75.07% |
| 2016-12-31 | $3.79 Million | $-8.71 Million | -2.299x | +24.10% |
| 2015-12-31 | $3.46 Million | $-10.50 Million | -3.029x | -142.01% |
| 2014-12-31 | $9.19 Million | $-11.50 Million | -1.252x | -772.10% |
| 2013-12-31 | $21.18 Million | $-3.04 Million | -0.144x | -261.24% |
| 2012-12-31 | $-19.66 Million | $-1.75 Million | 0.089x | -45.68% |
| 2011-12-31 | $-17.65 Million | $-2.89 Million | 0.164x | -- |
About Evoke Pharma Inc
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medi… Read more